Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

Bullboard (GREY:IPHAF)

View:
Comment by rickkuleszaon Jan 18, 2010 6:16am

RE: RE: Ranking

i think theses analysts enjoy cartwheels
Comment by blogon Jan 17, 2010 8:20pm

RE: Ranking

 Biostock01 AS you are aware,This is from another board;Those ranking doesn't means a lot. They are based on the analysts reports. So the ranking is just the compilation of analysts numbers ...more  
Post by Biostocks01on Jan 17, 2010 10:22am

Ranking

Look at the report ISA is number 7 of 700 compagnies. Any comments will be appreciate Have a nice day Biohttps://www.nasd100.com/2010/01/ranking-canadian-stocks-by-upside-potential-as-of-162009 ...more  
Comment by WASKERWISKon Jan 14, 2010 6:13pm

RE: RE: RE: RE: Royalties

sorry you are correct, 12%the hit on our upside  is 19% plus 12% of our remaining 81% works out to  19% + (.12x81%) = 28.72% plus bits and pieces so roughly 30%
Comment by MementoMorion Jan 14, 2010 5:15pm

Ignore the green highlighting in last post.

The green in my last post was a weird error, not an intended emphasis on the word 'payments'
Comment by MementoMorion Jan 14, 2010 4:23pm

RE: RE: RE: Royalties

> regarding the royalties and milestones, unfortunately, we pay 20% of that to Palladin.ISA pays Palladin 12%, not 20%. BTW that includes 12% on milestone payments.
Comment by throughmudon Jan 14, 2010 4:22pm

RE: RE: RE: RE: Royalties

Freud would have had a field day with that "will it to them" slip! mud
Comment by WASKERWISKon Jan 14, 2010 3:43pm

RE: RE: RE: Royalties

sorry, "sell it to them" not "will it to them"
Comment by WASKERWISKon Jan 14, 2010 3:42pm

RE: RE: Royalties

we also have a commercial supply agreement with Lux to manufacture the stuff i.e we will it to them and then they market it - not sure if there is a material profit in that or notregarding ...more  
Comment by throughmudon Jan 14, 2010 2:59pm

RE: Royalties

There is a royalty to be paid by Lux based on a percentage of net sales, but I believe that a percentage figure has not been made public.mud
Comment by MementoMorion Jan 14, 2010 2:57pm

RE: Royalties

> will isa get royalties on luveniq sales?> if so, what percentage of what?Lux will pay ISA royalties as a percentage of net sales, but as far as I know, the percentage has never been made ...more  
Post by biodelatechon Jan 14, 2010 2:00pm

Royalties

will isa get royalties on luveniq sales?if so, what percentage of what?
Comment by WASKERWISKon Jan 14, 2010 11:15am

RE: lux news

well, according to that article the NDA is only "days away"let's hope
Post by hopskipjumpon Jan 14, 2010 10:54am

lux news

https://www.fiercebiotech.com/story/san-francisco-treat/2010-01-14
Post by labumbaon Jan 13, 2010 7:20pm

a few words

go to google to dig out info about NDA.....you will be amused to find out that it is a timely process ....far more complicated than a " job application "
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities